JME
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Molecular Endocrinology (1996) 16, 39-44    DOI: 10.1677/jme.0.0160039
© 1996 Society for Endocrinology

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lowry, P J
Right arrow Articles by Rivier, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lowry, P J
Right arrow Articles by Rivier, J

Nature of ligand affinity and dimerization of corticotrophin-releasing factor-binding protein may be detected by circular dichroism

P J Lowry, S C Koerber, R J Woods, S Baigent, S Sutton, D P Behan, W Vale and J Rivier

As the association of corticotrophin-releasing factor (CRF) with its binding protein (BP) to form a dimer complex (CRF2/BP2) appears to be dependent on the nature of the ligand we have compared the circular dichroism difference spectra after association of the BP with ovine (o) CRF, human (h) CRF and the {alpha}-helical CRF(9–41) antagonist. All three ligands caused a negative change in molar ellipticity above 210 nm, with oCRF having the least and hCRF the greatest effect. Below 210 nm there was a marked divergence of difference spectra, with the reaction with the natural peptides, hCRF and oCRF, resulting in a positive change in ellipticity, whilst that with the antagonist produced a negative change. In view of the BP spectrum indicating predominantly β-sheet and the peptides showing mainly {alpha}-helix these results were interpreted as the changes above 210 nm being due to dimerization and below 210 nm to a change in the conformation of ligand on binding. The opposite change in {alpha}-helicity of the antagonist observed on binding compared with the two natural CRF peptides could have fundamental pharmacological implications.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Eckart, O. Jahn, J. Radulovic, H. Tezval, L. van Werven, and J. Spiess
A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: Implications for the design of agonists and antagonists
PNAS, September 25, 2001; 98(20): 11142 - 11147.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. J. Woods, C. F. Kemp, J. David, and P. J. Lowry
Heterogeneity of the Human Corticotropin-Releasing Factor-Binding Protein
J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1566 - 1571.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the Society for Endocrinology.